Souhaitez-vous accéder aux communiqués récents ?

Agios announces an agreement with Oscotec to license the exclusive global rights to cevidoplenib, a novel, next generation, oral SYK inhibitor

Agios provides update on Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes

PYRUKYND (mitapivat) approved in the European Union for adults with thalassemia

Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease

Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026

Agios announces first quarter 2026 financial results and provides business update.

Agios will report its first quarter 2026 financial results and business highlights on Wednesday, April 29, 2026.

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease

PYRUKYND (mitapivat) approved for adults with thalassemia in the United Arab Emirates

Agios (Nasdaq: AGIO) announces financial results and updates for the fourth quarter and year ended December 31, 2025.